Oncology
1 drug is in development for Large B-cell Lymphoma.
- Companies
- 1
- Clinical trials
- 23
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Large B-cell Lymphoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| sc262 | Sana Biotechnology, Inc. (SANA) |
About this indication
Large B-cell Lymphoma context
Oncology·MeSH: Lymphoma, Non-Hodgkin (D008228)
Narrower concept of MeSH descriptor Non-Hodgkin Lymphoma
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
Frequently asked questions
How many drugs are in development for Large B-cell Lymphoma?
BioSniper tracks 1 drug in development for Large B-cell Lymphoma across 1 company.
How many clinical trials target Large B-cell Lymphoma?
There are 23 clinical trials targeting Large B-cell Lymphoma tracked by BioSniper.
What is the prevalence of Large B-cell Lymphoma?
The estimated prevalence of Large B-cell Lymphoma is approximately 56.0 per 100,000 population.